```html

Hepatocellular Carcinoma (HCC) – A Complete Patient Guide

Overview

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, arising from hepatocytes – the main functional cells of the liver. It accounts for 75–85 % of all primary liver cancers and is the third leading cause of cancer‑related death worldwide.

Who it affects

• Adults > 50 years old are most frequently diagnosed, but HCC can occur at any age.
• Men are about 2–3 times more likely to develop HCC than women.
• Geographic variation is pronounced: the highest incidence is in East Asia and sub‑Saharan Africa, where chronic hepatitis B virus (HBV) infection is endemic.

Prevalence & statistics

• According to the World Health Organization (WHO), > 900,000 new cases are diagnosed each year worldwide (2023 estimate).<sup>1</sup>
• In the United States, the American Cancer Society reports ~ 42,000 new cases and ~ 30,000 deaths in 2024.<sup>2</sup>
• 5‑year survival varies widely: 70 % for very early stage disease detected through surveillance, but <10 % for advanced, non‑resectable tumors.<sup>3</sup>

Symptoms

Early HCC often produces no symptoms. When the tumor grows, patients may notice the following signs, which can differ based on tumor size, underlying liver disease, and whether complications such as portal hypertension develop.

General / Systemic

• Unexplained weight loss – loss of appetite and weight without trying.
• Fatigue – persistent tiredness that interferes with daily activities.
• Fever – low‑grade fevers may appear, especially if the tumor ruptures or becomes infected.

Abdominal

• Right upper‑quadrant pain or fullness – a dull ache or pressure beneath the rib cage.
• Abdominal distention – often from ascites (fluid buildup) due to impaired liver function.
• Palpable liver mass – a firm nodule felt during a physical exam.

Signs of Liver Dysfunction

• Jaundice – yellowing of the skin and eyes when bilirubin builds up.
• Pruritus – itching caused by bile salts accumulating in the skin.
• Dark urine / pale stools – result of altered bilirubin excretion.
• Easy bruising or bleeding – reduced production of clotting factors by the diseased liver.

Complication‑Specific Symptoms

• Portal hypertension – swelling of the abdomen (ascites), enlarged veins (caput medusae), or bleeding from esophageal varices (vomiting blood or coffee‑ground material).
• Hepatic encephalopathy – confusion, forgetfulness, or asterixis (hand‑flap tremor) due to toxin buildup.
• Tumor rupture – sudden severe abdominal pain, hypotension, and intra‑abdominal bleeding – a true emergency.

Causes and Risk Factors

HCC almost always develops in the setting of chronic liver injury. The liver’s regenerative capacity, while essential, also creates a fertile ground for malignant transformation when the regeneration is ongoing and dysregulated.

Major Causes

• Chronic hepatitis B infection – integrates viral DNA into hepatocyte genomes, directly promoting cancer. Risk persists even after viral clearance.<sup>4</sup>
• Chronic hepatitis C infection – induces inflammation and fibrosis that can progress to cirrhosis, the primary pre‑cancerous state.<sup>5</sup>
• Alcoholic liver disease – heavy, long‑term alcohol use (> 60 g/day for men, > 40 g/day for women) leads to cirrhosis.
• Non‑alcoholic fatty liver disease (NAFLD) / non‑alcoholic steatohepatitis (NASH) – now the fastest‑growing cause in Western countries.<sup>6</sup>
• Aflatoxin exposure – toxic metabolites from Aspergillus fungi contaminating stored grains and nuts, especially in warm, humid climates.

Additional Risk Factors

• Male sex (2–3× higher risk).
• Age > 50 years.
• Family history of HCC or chronic viral hepatitis.
• Diabetes mellitus and obesity (BMI ≥ 30 kg/m²) – increase NASH‑related HCC risk.
• Smoking – synergizes with viral hepatitis and alcohol.
• Inherited metabolic disorders (e.g., hemochromatosis, Wilson disease).
• Exposure to certain chemicals (vinyl chloride, thorotrast, anabolic steroids).

Diagnosis

Diagnosing HCC relies on a combination of imaging, blood tests, histology (when needed), and assessment of underlying liver disease. The goal is to confirm cancer, stage it, and evaluate liver reserve.

Initial Evaluation

• History & physical exam – focusing on risk factors, symptoms of liver disease, and signs of portal hypertension.
• Laboratory tests:
  • Liver function panel (AST, ALT, alkaline phosphatase, bilirubin, albumin, INR).
  • Complete blood count (CBC) – assesses anemia, thrombocytopenia.
  • Serum alpha‑fetoprotein (AFP) – elevated in ~ 60 % of HCC cases; a useful screening and monitoring marker, though not diagnostic alone.
  • Viral serologies (HBsAg, anti‑HBc, HCV RNA) and hepatitis B DNA when indicated.

Imaging Modalities

• Ultrasound (US) with Doppler – first‑line for surveillance; can detect focal lesions > 1 cm.
• Multiphasic contrast‑enhanced CT scan – arterial phase hyperenhancement with rapid washout in venous phase is characteristic for HCC.
• Dynamic contrast‑enhanced MRI – offers higher soft‑tissue contrast; hepatobiliary agents (e.g., gadoxetate) improve lesion characterization.
• Contrast‑enhanced ultrasound (CEUS) – useful when CT/MRI contraindicated.

International guidelines (AASLD, EASL) allow a diagnosis of HCC without a biopsy if a lesion ≥ 1 cm shows typical arterial enhancement and washout on two imaging modalities.

Biopsy

Reserved for atypical lesions, when imaging is inconclusive, or when a different cancer type is suspected. Percutaneous core‑needle biopsy carries a small risk of bleeding and tumor seeding.

Staging

Staging determines prognosis and treatment options. The most widely used system is the Barcelona Clinic Liver Cancer (BCLC) staging, which integrates tumor burden, liver function (Child‑Pugh score), performance status, and cancer‑related symptoms.

Treatment Options

Treatment is individualized based on tumor stage, liver function, patient performance status, and personal preferences. Multidisciplinary care (hepatology, oncology, surgery, interventional radiology, transplant) yields the best outcomes.

Curative‑Intent Therapies

• Surgical resection – Preferred for solitary tumors with preserved liver function (Child‑Pugh A). 5‑year survival can exceed 50 %.
• Liver transplantation – Indicated for patients meeting Milan criteria (single tumor ≤ 5 cm or up to 3 nodules ≤ 3 cm each) and decompensated cirrhosis. Provides both cancer cure and liver replacement; 5‑year survival > 70 %.
• Ablative therapies:
  • Radiofrequency ablation (RFA) or microwave ablation – effective for tumors ≤ 3 cm.
  • Irreversible electroporation (IRE) – useful near major vessels.

Locoregional (Bridge/Down‑Staging) Therapies

• Transarterial chemoembolization (TACE) – delivers chemotherapy directly to the tumor while blocking arterial supply; standard for intermediate‑stage (BCLC B) disease.
• Transarterial radioembolization (TARE) / Y‑90 – uses radioactive beads; beneficial for patients with portal vein thrombosis.
• Stereotactic body radiotherapy (SBRT) – high‑dose precise radiation for small lesions not amenable to ablation.

Systemic Therapies

Reserved for advanced (BCLC C) or unresectable disease.

• First‑line:
  • Immune checkpoint inhibitors (e.g., atezolizumab + bevacizumab) – superior overall survival vs. sorafenib (IMbrave150 trial).<sup>7</sup>
  • Sorafenib or lenvatinib – multi‑kinase inhibitors; still used when immunotherapy contraindicated.
• Second‑line:
  • Regorafenib, cabozantinib, ramucirumab (for AFP ≥ 400 ng/mL).
  • Nivolumab or pembrolizumab (PD‑1 inhibitors) – approved after sorafenib failure.

Supportive & Lifestyle Measures

• Management of underlying liver disease (antiviral therapy for HBV/HCV, abstinence from alcohol, weight loss for NAFLD).
• Nutritional support – adequate protein, calories, and supplements (vitamin D, zinc) to combat sarcopenia.
• Control of ascites and encephalopathy (diuretics, lactulose, rifaximin).
• Pain control and psychosocial counseling.

Living with Hepatocellular Carcinoma

Patients can improve quality of life and possibly outcomes by actively participating in their care.

Daily Management Tips

• Adhere to surveillance appointments – imaging every 3–6 months if awaiting transplant or after curative therapy.
• Take medications exactly as prescribed – antivirals, diuretics, systemic cancer drugs.
• Maintain a liver‑friendly diet:
  • Limit sodium (< 2 g/day) to reduce ascites.
  • Choose high‑quality protein (lean poultry, fish, tofu) while avoiding raw shellfish.
  • Eat plenty of fruits, vegetables, and whole grains; limit saturated fat and added sugars.
• Stay active – moderate walking or low‑impact activities 150 minutes/week, if approved by your provider.
• Vaccinations – hepatitis A & B, influenza, pneumococcal; discuss COVID‑19 boosters.
• Limit alcohol completely – even small amounts can exacerbate liver injury.
• Monitor for warning signs – new abdominal pain, increasing swelling, confusion, or vomiting blood.
• Seek psychosocial support – counseling, support groups, and palliative‑care services.

Follow‑up Care

Regular labs (CBC, liver panel, AFP) and imaging guide treatment response. A multidisciplinary clinic can coordinate care and address complications promptly.

Prevention

Because most HCC arises from preventable or treatable liver disease, primary and secondary prevention make a huge impact.

• Vaccinate against hepatitis B – universal infant vaccination has cut childhood HCC rates by > 70 % in endemic regions.<sup>8</sup>
• Screen & treat chronic HBV/HCV – antiviral therapy (e.g., entecavir, tenofovir for HBV; direct‑acting antivirals for HCV) reduces cirrhosis and HCC risk.
• Limit alcohol consumption – follow CDC guidelines (≤ 2 drinks/day for men, ≤ 1 drink/day for women) or abstain if liver disease exists.
• Maintain a healthy weight – target BMI 18.5–24.9 kg/m²; weight loss ≥ 5 % can improve NASH.
• Control diabetes & dyslipidemia – medications, diet, and exercise lower NAFLD progression.
• Reduce aflatoxin exposure – store grains/dry foods properly, discard moldy items.
• Avoid unnecessary liver‑toxic medications – acetaminophen > 4 g/day, certain herbal supplements.

Complications

If HCC is not adequately treated, a spectrum of serious complications may develop:

• Portal vein thrombosis – blocks blood flow, leading to worsening ascites and liver failure.
• Mass effect – large tumors can compress the bile ducts (obstructive jaundice) or stomach (early satiety, nausea).
• Spontaneous tumor rupture – intra‑abdominal hemorrhage, hypovolemic shock (high mortality).
• Liver decompensation – progression to Child‑Pugh C cirrhosis, encephalopathy, coagulopathy.
• Metastatic spread – lungs, bones, lymph nodes; leads to cachexia and further organ dysfunction.
• Secondary infections – ascites predisposes to spontaneous bacterial peritonitis.
• Hepatorenal syndrome – rapid kidney failure in the setting of advanced liver disease.

When to Seek Emergency Care

References

1. World Health Organization. Global Cancer Observatory: Liver Cancer Fact Sheet. 2023.
2. American Cancer Society. 2024 Cancer Facts & Figures.
3. Bruix J, et al. "EASL Clinical Practice Guidelines: Management of HCC." J Hepatol. 2022.
4. Lok ASF, McMahon BJ. "Chronic Hepatitis B: Update 2024." Hepatology. 2024.
5. Polaris P, et al. "HCV‑related HCC risk after cure with DAAs." Lancet Gastroenterol Hepatol. 2023.
6. Younossi ZM, et al. "NAFLD is the leading cause of HCC in the United States." Gastroenterology. 2023.
7. Llovet JM, et al. "Atezolizumab plus bevacizumab in unresectable HCC (IMbrave150)." NEJM. 2020.
8. Shi L, et al. "Impact of universal HBV vaccination on childhood liver cancer." BMJ. 2022.

```